Cargando…

A New, Objective, Quantitative Scale for Measuring Local Skin Responses Following Topical Actinic Keratosis Therapy with Ingenol Mebutate

INTRODUCTION: Local skin responses (LSRs) are the most common adverse effects of topical actinic keratosis (AK) therapy. There is currently no method available that allows objective characterization of LSRs. Here, the authors describe a new scale developed to quantitatively and objectively assess th...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosen, Robert, Marmur, Ellen, Anderson, Lawrence, Welburn, Peter, Katsamas, Janelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4257948/
https://www.ncbi.nlm.nih.gov/pubmed/25073700
http://dx.doi.org/10.1007/s13555-014-0059-9
_version_ 1782347822553628672
author Rosen, Robert
Marmur, Ellen
Anderson, Lawrence
Welburn, Peter
Katsamas, Janelle
author_facet Rosen, Robert
Marmur, Ellen
Anderson, Lawrence
Welburn, Peter
Katsamas, Janelle
author_sort Rosen, Robert
collection PubMed
description INTRODUCTION: Local skin responses (LSRs) are the most common adverse effects of topical actinic keratosis (AK) therapy. There is currently no method available that allows objective characterization of LSRs. Here, the authors describe a new scale developed to quantitatively and objectively assess the six most common LSRs resulting from topical AK therapy with ingenol mebutate. METHODS: The LSR grading scale was developed using a 0–4 numerical rating, with clinical descriptors and representative photographic images for each rating. Good inter-observer grading concordance was demonstrated in peer review during development of the tool. Data on the use of the scale are described from four phase III double-blind studies of ingenol mebutate (n = 1,005). RESULTS: LSRs peaked on days 4 (face/scalp) or 8 (trunk/extremities), with mean maximum composite LSR scores of 9.1 and 6.8, respectively, and a rapid return toward baseline by day 15 in most cases. Mean composite LSR score at day 57 was generally lower than at baseline. CONCLUSION: The LSR grading scale is an objective tool allowing practicing dermatologists to characterize and compare LSRs to existing and, potentially, future AK therapies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13555-014-0059-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4257948
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-42579482014-12-10 A New, Objective, Quantitative Scale for Measuring Local Skin Responses Following Topical Actinic Keratosis Therapy with Ingenol Mebutate Rosen, Robert Marmur, Ellen Anderson, Lawrence Welburn, Peter Katsamas, Janelle Dermatol Ther (Heidelb) Original Research INTRODUCTION: Local skin responses (LSRs) are the most common adverse effects of topical actinic keratosis (AK) therapy. There is currently no method available that allows objective characterization of LSRs. Here, the authors describe a new scale developed to quantitatively and objectively assess the six most common LSRs resulting from topical AK therapy with ingenol mebutate. METHODS: The LSR grading scale was developed using a 0–4 numerical rating, with clinical descriptors and representative photographic images for each rating. Good inter-observer grading concordance was demonstrated in peer review during development of the tool. Data on the use of the scale are described from four phase III double-blind studies of ingenol mebutate (n = 1,005). RESULTS: LSRs peaked on days 4 (face/scalp) or 8 (trunk/extremities), with mean maximum composite LSR scores of 9.1 and 6.8, respectively, and a rapid return toward baseline by day 15 in most cases. Mean composite LSR score at day 57 was generally lower than at baseline. CONCLUSION: The LSR grading scale is an objective tool allowing practicing dermatologists to characterize and compare LSRs to existing and, potentially, future AK therapies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13555-014-0059-9) contains supplementary material, which is available to authorized users. Springer Healthcare 2014-07-30 /pmc/articles/PMC4257948/ /pubmed/25073700 http://dx.doi.org/10.1007/s13555-014-0059-9 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Research
Rosen, Robert
Marmur, Ellen
Anderson, Lawrence
Welburn, Peter
Katsamas, Janelle
A New, Objective, Quantitative Scale for Measuring Local Skin Responses Following Topical Actinic Keratosis Therapy with Ingenol Mebutate
title A New, Objective, Quantitative Scale for Measuring Local Skin Responses Following Topical Actinic Keratosis Therapy with Ingenol Mebutate
title_full A New, Objective, Quantitative Scale for Measuring Local Skin Responses Following Topical Actinic Keratosis Therapy with Ingenol Mebutate
title_fullStr A New, Objective, Quantitative Scale for Measuring Local Skin Responses Following Topical Actinic Keratosis Therapy with Ingenol Mebutate
title_full_unstemmed A New, Objective, Quantitative Scale for Measuring Local Skin Responses Following Topical Actinic Keratosis Therapy with Ingenol Mebutate
title_short A New, Objective, Quantitative Scale for Measuring Local Skin Responses Following Topical Actinic Keratosis Therapy with Ingenol Mebutate
title_sort new, objective, quantitative scale for measuring local skin responses following topical actinic keratosis therapy with ingenol mebutate
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4257948/
https://www.ncbi.nlm.nih.gov/pubmed/25073700
http://dx.doi.org/10.1007/s13555-014-0059-9
work_keys_str_mv AT rosenrobert anewobjectivequantitativescaleformeasuringlocalskinresponsesfollowingtopicalactinickeratosistherapywithingenolmebutate
AT marmurellen anewobjectivequantitativescaleformeasuringlocalskinresponsesfollowingtopicalactinickeratosistherapywithingenolmebutate
AT andersonlawrence anewobjectivequantitativescaleformeasuringlocalskinresponsesfollowingtopicalactinickeratosistherapywithingenolmebutate
AT welburnpeter anewobjectivequantitativescaleformeasuringlocalskinresponsesfollowingtopicalactinickeratosistherapywithingenolmebutate
AT katsamasjanelle anewobjectivequantitativescaleformeasuringlocalskinresponsesfollowingtopicalactinickeratosistherapywithingenolmebutate
AT rosenrobert newobjectivequantitativescaleformeasuringlocalskinresponsesfollowingtopicalactinickeratosistherapywithingenolmebutate
AT marmurellen newobjectivequantitativescaleformeasuringlocalskinresponsesfollowingtopicalactinickeratosistherapywithingenolmebutate
AT andersonlawrence newobjectivequantitativescaleformeasuringlocalskinresponsesfollowingtopicalactinickeratosistherapywithingenolmebutate
AT welburnpeter newobjectivequantitativescaleformeasuringlocalskinresponsesfollowingtopicalactinickeratosistherapywithingenolmebutate
AT katsamasjanelle newobjectivequantitativescaleformeasuringlocalskinresponsesfollowingtopicalactinickeratosistherapywithingenolmebutate